{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:23Z","timestamp":1789506203069,"version":"build-2803163510"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Androgen deprivation therapy (ADT) remains the cornerstone of treatment for advanced, hormone-sensitive prostate cancer (HSPC), but responses are transient, and most patients ultimately develop castration-resistant prostate cancer (CRPC), a largely incurable stage of disease. The mechanisms driving resistance are not yet fully understood. Recent data suggest epigenetic dysregulation driven by alterations in chromatin remodelers and histone-modifying enzymes (HMEs) contributes significantly to prostate cancer (PC) progression and resistance to androgen-directed therapies. HMEs control chromatin structure and transcriptional programs, and their altered activity contributes to androgen resistance and tumor progression. HME inhibitors offer promising therapeutic potential, yet their effects are highly context-dependent, emphasizing the importance of biomarker-guided precision strategies and rational combination therapies. This review highlights the contribution of histone PTMs and HMEs to CRPC progression and discusses their potential as novel strategies to improve clinical outcomes.<\/jats:p>","DOI":"10.3389\/fendo.2025.1730397","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:02Z","timestamp":1768196702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Tanaya A.","family":"Purohit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Denu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Jarrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/RRU.S303215","article-title":"Evolution of androgen deprivation therapy (adt) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res Rep Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-018-0707-9","article-title":"Molecular subtypes of prostate cancer","volume":"20","author":"Arora","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5061","article-title":"Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)","author":"Schweizer","year":"2024","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-1141","article-title":"Synthetic lethal metabolic targeting of androgen-deprived prostate cancer cells with metformin","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discovery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2019.1634985","article-title":"Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3","volume":"14","author":"Lv","year":"2019","journal-title":"Epigenetics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81063-6","article-title":"Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation","volume":"84","author":"Brownell","year":"1996","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/35020506","article-title":"Regulation of chromatin structure by site-specific histone H3 methyltransferases","volume":"406","author":"Rea","year":"2000","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","article-title":"Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy","volume":"19","author":"Lu","year":"2020","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature21357","article-title":"Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer","volume":"542","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-1279","article-title":"BRD4 regulates metastatic potential of castration-resistant prostate cancer through AHNAK","volume":"17","author":"Shafran","year":"2019","journal-title":"Mol Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01893-6","article-title":"NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis","volume":"56","author":"Parolia","year":"2024","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discovery"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"119085","DOI":"10.1016\/j.bbamcr.2021.119085","article-title":"AMPK\/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells","volume":"1868","author":"Natani","year":"2021","journal-title":"Biochim Biophys Acta (BBA)-Molecular Cell Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000130315","article-title":"X inactivation, differentiation, and DNA methylation","volume":"14","author":"Riggs","year":"1975","journal-title":"Cytogenet Cell Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.187.4173.226","article-title":"DNA modification mechanisms and gene activity during development","volume":"187","author":"Holliday","year":"1975","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.003","article-title":"Distinct factors control histone variant H3","volume":"140","author":"Goldberg","year":"2010","journal-title":"3 localization at specific genomic regions. Cell"},{"key":"B31","volume-title":"Handbook of Epigenetics : The New Molecular and Medical Genetics","author":"Tollefsbol T","year":"2017"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.6b01035","article-title":"Identifying dysregulated epigenetic enzyme activity in castrate-resistant prostate cancer development","volume":"12","author":"Lee","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1186\/s12885-017-3853-9","article-title":"Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes","volume":"17","author":"Damodaran","year":"2017","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28477","article-title":"Development of a multiplex assay to assess activated p300\/CBP in circulating prostate tumor cells","volume":"14","author":"Filon","year":"2023","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167440","article-title":"LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function","volume":"8","author":"Kumaraswamy","year":"2023","journal-title":"JCI Insight"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","author":"Luo","year":"2025","journal-title":"Nat Genet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.10.020","article-title":"Inhibition of H3K18 deacetylation of Sirt7 by Myb-binding protein 1a (Mybbp1a)","volume":"441","author":"Karim","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.06.182","article-title":"Levels of histone acetylation in thyroid tumors","volume":"411","author":"Puppin","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PRCA2023-A060","article-title":"Abstract A060: Genetic alterations induce distinct histone post-translational modifications during the transition to castration-resistant prostate cancer","author":"Purohit","year":"2023"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2312","article-title":"Chromatin remodelers Isw1 and Chd1 maintain chromatin structure during transcription by preventing histone exchange","volume":"19","author":"Smolle","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.30506","article-title":"Chromatin accessibility underlies synthetic lethality of SWI\/SNF subunits in ARID1A-mutant cancers","volume":"6","author":"Kelso","year":"2017","journal-title":"Elife"},{"key":"B44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41594-017-0007-3","article-title":"Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers","volume":"25","author":"Hodges","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4222","article-title":"Loss of ARID1A in Tumor cells renders selective vulnerability to combined ionizing radiation and parp inhibitor therapy","volume":"25","author":"Park","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-016-0223-4","article-title":"Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy","volume":"8","author":"Morera","year":"2016","journal-title":"Clin Epigenetics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00975-3","article-title":"Drosophila enhancer of Zeste\/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites","volume":"111","author":"Czermin","year":"2002","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01398-7","article-title":"Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype","volume":"125","author":"Filon","year":"2021","journal-title":"Br J Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"21396","DOI":"10.1038\/s41598-021-00889-0","article-title":"EZH1\/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma","volume":"11","author":"Kusakabe","year":"2021","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting Excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-013-2093-2","article-title":"EZH2, an epigenetic driver of prostate cancer","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.03.018","article-title":"An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression","volume":"17","author":"Yu","year":"2010","journal-title":"Cancer Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.18632\/oncotarget.v5i16","article-title":"EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer","volume":"5","author":"Chinaranagari","year":"2014","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/carcin\/bgu238","article-title":"Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy","volume":"36","author":"Takeshima","year":"2015","journal-title":"Carcinogenesis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe2261","article-title":"Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer","volume":"7","author":"Park","year":"2021","journal-title":"Sci Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"216815","DOI":"10.1016\/j.canlet.2024.216815","article-title":"Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer","volume":"588","author":"Kanaoka","year":"2024","journal-title":"Cancer Lett"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1038\/s41467-018-07511-4","article-title":"NSD2 is a conserved driver of metastatic prostate cancer progression","volume":"9","author":"Aytes","year":"2018","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S259873","article-title":"The role of methyltransferase NSD2 as a potential oncogene in human solid tumors","volume":"13","author":"Chen","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.05.038","article-title":"The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription","volume":"583","author":"Kang","year":"2009","journal-title":"FEBS Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00204-12","article-title":"Histone methyltransferase NSD2\/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop","volume":"32","author":"Yang","year":"2012","journal-title":"Mol Cell Biol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91144","article-title":"AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis","volume":"127","author":"Li","year":"2017","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.297","article-title":"The histone methyltransferase MMSET\/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer","volume":"32","author":"Ezponda","year":"2013","journal-title":"Oncogene"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0083","article-title":"PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage","volume":"9","author":"Zhang","year":"2019","journal-title":"Cancer Discovery"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e2305684120","DOI":"10.1073\/pnas.2305684120","article-title":"Tiam1 methylation by NSD2 promotes Rac1 signaling activation and colon cancer metastasis","volume":"120","author":"Song","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.molcel.2012.10.008","article-title":"Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer","volume":"49","author":"Asangani","year":"2013","journal-title":"Mol Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00948","article-title":"Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)","volume":"66","author":"Ma","year":"2023","journal-title":"J Med Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3830","article-title":"Targeting the MLL complex in castration-resistant prostate cancer","volume":"21","author":"Malik","year":"2015","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02039-2","article-title":"Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity","volume":"41","author":"Cherif","year":"2022","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.12659\/MSM.912294","article-title":"Integrated analysis of genetic abnormalities of the histone lysine methyltransferases in prostate cancer","volume":"25","author":"Zhang","year":"2019","journal-title":"Med Sci Monit"},{"key":"B71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/ERC-13-0375","article-title":"Deregulated expression of selected histone methylases and demethylases in prostate carcinoma","volume":"21","author":"Vieira","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e2114324119","DOI":"10.1073\/pnas.2114324119","article-title":"H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer","volume":"119","author":"Baratchian","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B73","article-title":"EHMT2 promotes the development of prostate cancer by inhibiting PI3K\/AKT\/mTOR pathway","volume":"23","author":"Fan","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v113.7","article-title":"Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription","volume":"113","author":"Purcell","year":"2012","journal-title":"J Cell Biochem"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404210","article-title":"DOT1L-HES6 fusion drives androgen independent growth in prostate cancer","volume":"6","author":"Annala","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-020-18013-7","article-title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer","volume":"11","author":"Vatapalli","year":"2020","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature04020","article-title":"LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription","volume":"437","author":"Metzger","year":"2005","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2433","article-title":"LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1719168115","article-title":"LSD1 activates a lethal prostate cancer gene network independently of its demethylase function","volume":"115","author":"Sehrawat","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802415115","article-title":"Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells","volume":"115","author":"Fan","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.309","article-title":"Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival","volume":"35","author":"Fan","year":"2016","journal-title":"Oncogene"},{"key":"B82","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41419-020-2405-4","article-title":"Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells","volume":"11","author":"Fan","year":"2020","journal-title":"Cell Death Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1116-8","article-title":"Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer","volume":"39","author":"Sarac","year":"2020","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","first-page":"114077","DOI":"10.1016\/j.biopha.2022.114077","article-title":"Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer","volume":"158","author":"Duan","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz1004","article-title":"Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation","volume":"47","author":"Duan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600420113","article-title":"Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression","volume":"113","author":"Komura","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1124\/molpharm.121.000372","article-title":"Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression","volume":"101","author":"Yildirim-Buharalioglu","year":"2022","journal-title":"Mol Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12310","article-title":"c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer","volume":"7","author":"Maina","year":"2016","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1038\/oncsis.2016.74","article-title":"The HIF\/PHF8\/AR axis promotes prostate cancer progression","volume":"5","author":"Tong","year":"2016","journal-title":"Oncogenesis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122872","article-title":"CBP\/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers","volume":"13","author":"Waddell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B91","unstructured":"2025"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.5050","article-title":"LBH589 (LBH) and bicalutamide (Bic) in castration-resistant prostate cancer (CRPC) patients (pts) progressing on second line anti-androgen (AA): NYU-08479\/PCCTC","author":"Ferrari","year":"2015","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5112","article-title":"VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer","author":"Raychaudhuri","year":"2025","journal-title":"Am Soc Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0252-4","article-title":"A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195","volume":"33","author":"Eigl","year":"2015","journal-title":"Invest New Drugs"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3043","article-title":"Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors","author":"Burness","year":"2025","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1461","article-title":"A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas","volume":"14","author":"Gore","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp270","article-title":"two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8020022","article-title":"Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer","volume":"8","author":"Rana","year":"2020","journal-title":"Biomedicines"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4121","article-title":"Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor gsk2816126 in patients with advanced hematologic and solid tumors","volume":"25","author":"Yap","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"S967","DOI":"10.1016\/j.annonc.2024.08.1684","article-title":"1603P Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Abida","year":"2024","journal-title":"Ann Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01800-5","article-title":"Valemetostat tosilate: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B103","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.ejca.2024.115122","article-title":"A first-in-human phase 1\/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies","volume":"216","author":"Ribrag","year":"2025","journal-title":"Eur J Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c01421","article-title":"Discovery of a potent and selective targeted NSD2 degrader for the reduction of H3K36me2","volume":"145","author":"Hanley","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-024-01660-y","article-title":"Recruitment of FBXO22 for targeted degradation of NSD2","volume":"20","author":"Nie","year":"2024","journal-title":"Nat Chem Biol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c01765","article-title":"Discovery of LLC0424 as a potent and selective in vivo NSD2 PROTAC ddegrader","volume":"67","author":"Liu","year":"2024","journal-title":"J Med Chem"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073026","article-title":"Menin-MLL1 interaction small molecule inhibitors: a potential therapeutic strategy for leukemia and cancers","volume":"28","author":"Shi","year":"2023","journal-title":"Molecules"},{"key":"B109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00978","article-title":"Discovery of CC-90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1)","volume":"63","author":"Kanouni","year":"2020","journal-title":"J Medicinal Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6589","article-title":"Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1\/HDAC6): An opportunity to treat essential thrombocythemia and MPN\/MDS patients with thrombocytosis in ongoing phase 1\/2 clinical trial","author":"Dolan","year":"2025","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","author":"Li","year":"2025","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/mol2.2018.12.issue-11","article-title":"Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations","volume":"12","author":"Macheleidt","year":"2018","journal-title":"Mol Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1021\/prechem.5c00014","article-title":"Advances in epigenomic sequencing and their applications in cancer diagnostics","volume":"3","author":"Lin","year":"2025","journal-title":"Precis Chem"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1730397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:45:12Z","timestamp":1768196712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1730397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":115,"alternative-id":["10.3389\/fendo.2025.1730397"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1730397","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1730397"}}